"Galektiny v dla\u017Edicov\u00FDch karcinomech hlavy a krku"@cs . . "Dvo\u0159\u00E1nkov\u00E1, Barbora" . . "Chovanec, Martin" . . "Cancers of head and neck represents about 5% of all tumors. 80 to 90% of these tumors are constituted of squamous cell carcinomas. Despite a rapid progress in diagnostics and therapy the overall 5-year survival of this type of cancer is among the lowest of the major cancer types. This unfavourable situation needs the extensive research to found new markers to better characterize biological behavior of tumors as a rational background for more sophisticated therapeutic modalities. Among the most promising markers are endogenous lectins called galectins and their ligands. Especially galectin-1, -3 and -7 play a key role in pathology of squamous cell carcinomas."@en . . "0008-7335" . . . . "5"^^ . "Lacina, Luk\u00E1\u0161" . . "\u010Cada, Zden\u011Bk" . . "147" . "Betka, Jan" . "Szab\u00F3, Pavol" . "[ABA909332865]" . "http://www.medvik.cz/link/bmc07516354" . "8"^^ . "368910" . . "\u010Casopis l\u00E9ka\u0159\u016F \u010Desk\u00FDch" . "Galektiny v dla\u017Edicov\u00FDch karcinomech hlavy a krku" . . "Galectins in suamous cell carcinomas of the head and neck cancers"@en . "RIV/00216208:11130/08:6906" . "11" . . "Plz\u00E1k, Jan" . "Galektiny v dla\u017Edicov\u00FDch karcinomech hlavy a krku"@cs . . "I, P(GP304/08/P175), P(NR9049)" . "5"^^ . "N\u00E1dory hlavy a krku tvo\u0159\u00ED kolem 5 % v\u0161ech n\u00E1dor\u016F. Osmdes\u00E1t a\u017E devades\u00E1t procent t\u011Bchto n\u00E1dor\u016F je p\u0159edstavov\u00E1no dla\u017Edicov\u00FDmi karcinomy. I p\u0159es rozvoj chirurgick\u00FDch poznatk\u016F a metod v\u010Detn\u011B onkologick\u00FDch l\u00E9\u010Debn\u00FDch re\u017Eim\u016F, je terapie t\u011Bchto tumor\u016F sv\u00EDzeln\u00E1 a p\u011Btilet\u00E9 p\u0159e\u017Eit\u00ED u pokro\u010Dil\u00FDch n\u00E1dor\u016F je st\u00E1le velmi n\u00EDzk\u00E9. \u0158e\u0161en\u00EDm situace je hled\u00E1n\u00ED nov\u00FDch znak\u016F (marker\u016F), kter\u00E9 by l\u00E9pe charakterizovaly tyto n\u00E1dory a napomohly tak p\u0159i up\u0159esn\u011Bn\u00ED l\u00E9\u010Debn\u00E9 strategie. Jedn\u00EDm z t\u011Bchto znak\u016F by mohly b\u00FDt endogenn\u00ED lektiny zvan\u00E9 galektiny a jejich ligandy. V patologii dla\u017Edicov\u00FDch karcinom\u016F hlavy a krku se nejv\u00EDce uplat\u0148uj\u00ED galektin-1, -3 a -7." . . "Smetana, Karel" . "RIV/00216208:11130/08:6906!RIV13-MSM-11130___" . . . . "N\u00E1dory hlavy a krku tvo\u0159\u00ED kolem 5 % v\u0161ech n\u00E1dor\u016F. Osmdes\u00E1t a\u017E devades\u00E1t procent t\u011Bchto n\u00E1dor\u016F je p\u0159edstavov\u00E1no dla\u017Edicov\u00FDmi karcinomy. I p\u0159es rozvoj chirurgick\u00FDch poznatk\u016F a metod v\u010Detn\u011B onkologick\u00FDch l\u00E9\u010Debn\u00FDch re\u017Eim\u016F, je terapie t\u011Bchto tumor\u016F sv\u00EDzeln\u00E1 a p\u011Btilet\u00E9 p\u0159e\u017Eit\u00ED u pokro\u010Dil\u00FDch n\u00E1dor\u016F je st\u00E1le velmi n\u00EDzk\u00E9. \u0158e\u0161en\u00EDm situace je hled\u00E1n\u00ED nov\u00FDch znak\u016F (marker\u016F), kter\u00E9 by l\u00E9pe charakterizovaly tyto n\u00E1dory a napomohly tak p\u0159i up\u0159esn\u011Bn\u00ED l\u00E9\u010Debn\u00E9 strategie. Jedn\u00EDm z t\u011Bchto znak\u016F by mohly b\u00FDt endogenn\u00ED lektiny zvan\u00E9 galektiny a jejich ligandy. V patologii dla\u017Edicov\u00FDch karcinom\u016F hlavy a krku se nejv\u00EDce uplat\u0148uj\u00ED galektin-1, -3 a -7."@cs . "CZ - \u010Cesk\u00E1 republika" . . "Galectins in suamous cell carcinomas of the head and neck cancers"@en . . . "Galektiny v dla\u017Edicov\u00FDch karcinomech hlavy a krku" . "11130" . . "Squamous cell carcinomas; galectins; prognostic markers"@en .